Advocates for the tax say it could help defray treatment costs, but not everyone thinks it's a good idea.
In the fight against the nation’s epidemic of opioid and heroin addiction, states have enhanced prescription registries, armed first responders with naloxone, and capped the number of days on the first prescription. Earlier this year, New Jersey took just over 30 days to create new mandates for insurers to get people in treatment when they are ready to go.
Now, some states are weighing a new tool—a special tax on prescription opioids, which proponents say would discourage use. Both California and Alaska lawmakers are weighing 1-cent-per-milligram taxes, with advocates for the California tax saying it would raise tens of millions of dollars for treatment.
In Congress, US Senator Joe Manchin, D-West Virginia, has re-introduced a federal opioid tax to fund treatment; his state has the highest per-capita death rate from opioids in the nation.
Advocates for the tax say it’s a way to make drug companies and wholesalers help pay treatment costs after the suppliers have been blamed for fueling the addiction crisis in the first place. (This week, a reporter from the Charleston, West Virginia, Gazette-Mail won the Pulitzer Prize for documenting the role of wholesalers in creating an oversupply of prescription opioids in his state.)
But critics of the tax strongly disagree with this approach, and say the costs will be passed to people with pain who are using the drugs legally. In a commentary that appeared in several Alaska news outlets, Paul Jenkins wrote that an opioid tax, “muscles the state into the doctor-patient relationship, and selling the tax as a way to reduce painkillers’ use is disingenuous.”
Opinion over a tax may be split, but data on the opioid crisis are clear: CDC reports that the number of prescriptions quadrupled between 1999 and 2014, and so did the number of overdoses. About 2 million people were addicted or abusing prescription painkillers by 2014, and the recent rise of the synthetic opioid fentanyl has only made things worse for public health officials and emergency responders.
Cigarette taxes have been a key tool in reducing smoking rates over the past 5 decades, but those taxes are levied at the point of sale. And unlike opioids, which can have a legitimate medical use, tobacco use is universally discouraged by public health experts.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen